Remedy Plan Therapeutics to Present Results from Phase 1 Healthy Volunteer Study of NAMPT Inhibitor RPT1G and Other Progress at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Parisa Moghaddam-Taaheri on December 1, 2025 in Media

Read More

Remedy Plan Therapeutics Advances RPT1G for Myeloid Cancer Patients with Phase 1 Safety Data and IND Approval

Parisa Moghaddam-Taaheri on November 1, 2025 in Media

Read More

Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials

Parisa Moghaddam-Taaheri on May 1, 2025 in Media

Read More

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor

Parisa Moghaddam-Taaheri on December 1, 2024 in Media

Read More

UPDATE - Remedy Plan Therapeutics Showcases Preclinical Data from First-In-Class NAMPT Inhibitor, RPT1G, Demonstrating Synergy with BCL-2 Family Inhibitors in AML at the 2024 ASH Annual Meeting

Parisa Moghaddam-Taaheri on December 1, 2024 in Media

Read More

• « Older